Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma

Song, YQ; Zhou, KS; Yang, SM; Hu, JD; Zou, DH; Gao, SJ; Pan, L; Wang, TY; Yang, HY; Zhang, HL; Zhou, DB; Ji, J; Xu, W; Feng, R; Jin, J; Lv, FF; Huang, HW; Fan, XS; Xu, S; Zhu, J

Song, YQ; Zhu, J (通讯作者)，Peking Univ Canc Hosp & Inst, Dept Lymphoma, Beijing Canc Hosp, 52 Fucheng Rd, Beijing 100142, Peoples R China.

INVESTIGATIONAL NEW DRUGS, 2023; 41 (4): 606

Abstract

We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索